In preclinical mouse models, STING-agonists such as DMXAA were shown to be effective for tumor regression by triggering the cooperation between T cells and myeloid cells [125], thereby causing them to enhance CAR-T cell trafficking to the tumor site [126]. The gene discussed is STING1; the disease is neoplasm.